Non-invasive treatment for healing vocal fold injuries
Official title: Non-invasive Therapy using Lamina Propria Extract for Vocal Fold Healing
Funded at North Carolina State University Raleigh · NIH-11073855 · Data updated 2026-11-12
This study is testing a new treatment using a special extract to help heal vocal fold injuries and scarring, which could offer a safer, non-invasive option for people with voice problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project start | December 15, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $633,694 |
| NIH project number | 1R01DC022510-01 |
| Project ID | NIH-11073855 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include individuals with vocal fold scarring or laryngotracheal injuries who are seeking alternative treatments.
✕Less likely to help
Patients with non-vocal fold related voice disorders or those who have already undergone extensive surgical interventions may not benefit from this research.
What this research studies
This research investigates a novel treatment using Vocal Fold Lamina Propria extract (VFLPx) to heal vocal fold injuries and scarring. The approach involves fine-tuning the dosage and application methods of VFLPx, which has shown promise in reducing harmful fibrotic gene expression. The study will assess the effectiveness of VFLPx in promoting wound healing in a rabbit model and evaluate its safety through nebulized delivery in a rat model, aiming to minimize the need for invasive surgeries. Patients may benefit from a non-invasive option for treating voice disorders.
Why it matters
Potential benefit: If successful, this research could provide a non-invasive treatment option for millions suffering from voice disorders.
How similar studies have gone: Previous research has shown promise in using similar non-invasive therapies for tissue healing, suggesting potential success for this approach.
Where this research is happening
-
North Carolina State University Raleigh
Raleigh, United States Active
Researchers
- Principal investigator: Freytes, Donald O — North Carolina State University Raleigh
- Study coordinator: Freytes, Donald O
Related research
Other NIH-funded projects on the same topics.
-
Brewing anti-toxin drugs using probiotic yeast
A studying team will develop probiotic yeast–based anti-toxin drugs to help treat gut bacterial infections and reduce antibiotic-related complications.
-
Small Ruminant Therapeutic Center to Speed Safe Drugs for Sheep and Goats
A pilot project at a university will help scientists and veterinarians speed up and improve how drugs are tested and approved for sheep and goats.
-
Metabolic effects of PFAS exposure in the Cape Fear Basin (GenX Exposure Study)
This NIH grant studies how PFAS chemicals in drinking water may affect metabolism and weight-related health in adults and children living along the Cape Fear River.
-
Understanding how Fe/2OG enzymes make pharmacophores like cyclopropane, aziridine, and isonitrile groups
A research project at a university aims to uncover how nonheme-iron enzymes create key drug-building rings and groups to help develop better biocatalysts and medicines.
-
Hemostatic B-knob Microgels for Pediatric Bleeding
A kid-friendly hemostatic therapy using age-tuned microgels to stop dangerous bleeding after injury in children.
-
How cyanotoxins may harm nerve cells in ALS
This grant studies how shared toxins from cyanobacteria might worsen nerve damage in people with ALS.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.